350 related articles for article (PubMed ID: 20689997)
1. Perspectives in drug development for metastatic renal cell cancer.
Basu B; Eisen T
Target Oncol; 2010 Jun; 5(2):139-56. PubMed ID: 20689997
[TBL] [Abstract][Full Text] [Related]
2. Strategies to overcome therapeutic resistance in renal cell carcinoma.
Siska PJ; Beckermann KE; Rathmell WK; Haake SM
Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
Biswas S; Eisen T
Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
5. Treatment of renal cell carcinoma: Current status and future directions.
Barata PC; Rini BI
CA Cancer J Clin; 2017 Nov; 67(6):507-524. PubMed ID: 28961310
[TBL] [Abstract][Full Text] [Related]
6. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy and targeted therapy combinations in renal cancer.
McDermott DF
Curr Clin Pharmacol; 2011 Aug; 6(3):207-13. PubMed ID: 21827391
[TBL] [Abstract][Full Text] [Related]
8. How far is the horizon? From current targets to future drugs in advanced renal cancer.
Kruck S; Merseburger AS; Stenzl A; Bedke J
World J Urol; 2014 Feb; 32(1):69-77. PubMed ID: 23657355
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Raman R; Vaena D
Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
[TBL] [Abstract][Full Text] [Related]
10. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
11. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
13. Ongoing Screening and Treatment to Potentially Reduce Tyrosine Kinase Inhibitor-Related Fatigue in Renal Cell Carcinoma.
Anand D; Escalante CP
J Pain Symptom Manage; 2015 Jul; 50(1):108-17. PubMed ID: 25701692
[TBL] [Abstract][Full Text] [Related]
14. Recent advances and future directions in the management of metastatic renal cell carcinoma.
Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA
Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of mTor inhibitors for renal cancer.
Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
[TBL] [Abstract][Full Text] [Related]
16. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
17. Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines.
Rodriguez AR; Fishman MN
Expert Opin Pharmacother; 2007 Dec; 8(17):2979-90. PubMed ID: 18001257
[TBL] [Abstract][Full Text] [Related]
18. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
19. [mTOR inhibitors].
Oya M
Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
[TBL] [Abstract][Full Text] [Related]
20. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]